Which of the following is NOT typically considered a first-line disease-modifying therapy for relapsing MS?

Prepare for the PANCE Neurology Test with comprehensive materials. Use flashcards and multiple-choice questions, each featuring hints and explanations. Boost your confidence and ace your exam!

Multiple Choice

Which of the following is NOT typically considered a first-line disease-modifying therapy for relapsing MS?

First-line disease-modifying therapies for relapsing MS are chosen for a balance of safety and moderate efficacy. Interferon beta and glatiramer acetate have long safety records and modest efficacy, making them classic first-line options. Fingolimod is an oral therapy with greater efficacy than those two and is widely used as a first-line choice when aiming for stronger disease control. Ocrelizumab, a CD20-directed antibody, offers strong suppression of relapses and MRI activity, reflecting high potency. However, it comes with higher risks (infections, infusion reactions, potential safety signals with long-term immune effects) and is generally reserved for patients who do not respond adequately to first-line therapies or those with highly active disease. Because of its higher efficacy and risk profile, it is not typically used as an initial, first-line therapy for relapsing MS.

First-line disease-modifying therapies for relapsing MS are chosen for a balance of safety and moderate efficacy. Interferon beta and glatiramer acetate have long safety records and modest efficacy, making them classic first-line options. Fingolimod is an oral therapy with greater efficacy than those two and is widely used as a first-line choice when aiming for stronger disease control.

Ocrelizumab, a CD20-directed antibody, offers strong suppression of relapses and MRI activity, reflecting high potency. However, it comes with higher risks (infections, infusion reactions, potential safety signals with long-term immune effects) and is generally reserved for patients who do not respond adequately to first-line therapies or those with highly active disease. Because of its higher efficacy and risk profile, it is not typically used as an initial, first-line therapy for relapsing MS.

More practice questions